logo
logo

Intrance Medical Systems Completes $17 Million Series A Financing And Appoints Ed Schutter To Board Of Directors

Jan 04, 2022•over 3 years ago

Amount Raised

$17 Million

Round Type

series a

Stockholm

Description

Intrance Medical Systems Inc., a subsidiary of Sweden-based Intrance Holdings AB, today announced that it has completed the final round of a Series A financing, totaling USD $17 million. Internationally well renowned Scandinavian investors, Erik Selin and Rutger Arnhult, participated in the financing as anchor investors. Proceeds from the financing will enable Intrance to initiate pivotal U.S. clinical trials for the company’s lead product, a fixed-dose combination treatment of carbidopa, entacapone and levodopa for enteral infusion in advanced Parkinson’s disease patients

Company Information

Company

Intrance Medical Systems

Location

Stockholm, Stockholm County, Sweden

About

Intrance Medical Systems, Inc., a subsidiary of Sweden-based Intrance Holdings AB, is a private biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease in the U.S., Canada, South America, Japan and Taiwan. Intrance’s lead product, known as Lecigon® in the Nordic countries and certain European markets, is a fixed-dose combination treatment of levodopa, carbidopa and entacapone for enteral infusion in advanced Parkinson’s disease patients. The company is planning to advance its U.S. clinical development program in this target indication and recently filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). For more information, visit intrancemedical.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech